Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1996-3-7
pubmed:abstractText
We investigated hemostatic abnormalities in 37 patients with deep vein thrombosis (DVT) and pulmonary embolism (PE) (PE patients) and in 40 patients with DVT without PE (DVT patients). Plasma fibrinogen, thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex, fibrin-D-dimer, activated protein C (APC)-protein C inhibitor (PCI) complex, von Willebrand factor (vWf), tissue plasminogen activator (t-PA), PA inhibitor-I (PAI-1), and thrombomodulin levels in both PE and DVT patients were significantly increased compared with normal volunteers. Plasma APC-PCI complex, PAI-1, and vWf levels in PE patients were significantly higher than those in DVT patients without PE. These findings indicate that PE patients are more hypercoagulable and hypofibrinolytic than DVT patients. Plasma TAT, APC-PCI complex, PAI-1, and vWf levels were the most sensitive indicators for PE. In these patients, increases in TAT and APC-PCI complex suggest DVT and increased PAI-1 and vWf suggest the risk of onset of PE.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antithrombin III, http://linkedlifedata.com/resource/pubmed/chemical/Fibrin Fibrinogen Degradation..., http://linkedlifedata.com/resource/pubmed/chemical/Fibrinogen, http://linkedlifedata.com/resource/pubmed/chemical/Peptide Hydrolases, http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen Activator Inhibitor 1, http://linkedlifedata.com/resource/pubmed/chemical/Protein C, http://linkedlifedata.com/resource/pubmed/chemical/Protein C Inhibitor, http://linkedlifedata.com/resource/pubmed/chemical/Tissue Plasminogen Activator, http://linkedlifedata.com/resource/pubmed/chemical/antithrombin III-protease complex, http://linkedlifedata.com/resource/pubmed/chemical/fibrin fragment D, http://linkedlifedata.com/resource/pubmed/chemical/von Willebrand Factor
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0957-5235
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
627-33
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:8562833-Aged, pubmed-meshheading:8562833-Antithrombin III, pubmed-meshheading:8562833-Blood Coagulation Disorders, pubmed-meshheading:8562833-Female, pubmed-meshheading:8562833-Fibrin Fibrinogen Degradation Products, pubmed-meshheading:8562833-Fibrinogen, pubmed-meshheading:8562833-Humans, pubmed-meshheading:8562833-Male, pubmed-meshheading:8562833-Middle Aged, pubmed-meshheading:8562833-Partial Thromboplastin Time, pubmed-meshheading:8562833-Peptide Hydrolases, pubmed-meshheading:8562833-Plasminogen Activator Inhibitor 1, pubmed-meshheading:8562833-Protein C, pubmed-meshheading:8562833-Protein C Inhibitor, pubmed-meshheading:8562833-Prothrombin Time, pubmed-meshheading:8562833-Pulmonary Embolism, pubmed-meshheading:8562833-Thrombophlebitis, pubmed-meshheading:8562833-Tissue Plasminogen Activator, pubmed-meshheading:8562833-von Willebrand Factor
pubmed:year
1995
pubmed:articleTitle
Hemostatic abnormalities in patients with pulmonary embolism compared with that in deep vein thrombosis.
pubmed:affiliation
First Department of Internal Medicine, Mie University School of Medicine, Japan.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't